Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 06 Mar 2023
USA: The syrup drug Diethylene glycol (DEG), a drug commonly used to prevent infections, is the cause of kidney disease...
Read Full NewsA recent trial assesses whether the addition of quizartinib following intensive chemotherapy improves survival outcomes in older patients with previously untreated AML.
The newly approved inhibitor is for patients who previously received another drug of the same class.
1.
Cancer Warnings on Alcohol? Surge in GI Illnesses; Swab Detects Kids' Asthma Type
2.
The White House has postponed its plan to outlaw menthol cigarettes indefinitely.
3.
Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study
4.
Significant worldwide disparities seen in availability and timeliness of new cancer drugs
5.
Limited Benefit from New Drugs; Significant Increase in Drug Prices; AI Boost for Mammo Results.
1.
A Clinical Review of Novel Therapeutics for Rare Cancers in the Genomics Era
2.
Hematopoietic Recovery Potential and Long-Term Survival: Mechanisms, Clinical Impact, and Emerging Directions
3.
Revolutionizing Cancer Treatment: The Promise of Bevacizumab Injections
4.
Expanding Oncology Frontiers: Rare Cancers, Breakthroughs, and Precision Medicine Advances
5.
HPV-Related Cervical Cancer: Advances in Screening, Preventiofn & Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part VIII
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII
3.
Current Cancer Scenario in India- Importance of Genomic Testing & Advancement in Diagnosis and Treatment
4.
Exploring the Hospitalization Burden in Refractory and Relapsed ALL
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge